Viatris (VTRS) AI Stock Analysis

• Market Cap: $12.31B
• Dividend Yield: 4.49%
• Average Volume (3M): 8.81M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: -6.40%
• EPS Growth: -320.23%
• Country: US
• Employees: 32,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.67
• Shares Outstanding: 1,151,769,900
• 10 Day Avg. Volume: 8,017,539
• 30 Day Avg. Volume: 8,809,306
• PEG Ratio: 0.02
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 1.01
• P/FCF Ratio: 7.52
• Enterprise Value/Market Cap: 2.04
• Enterprise Value/Revenue: 1.78
• Enterprise Value/Gross Profit: 4.94
• Enterprise Value/Ebitda: -41.98
• 1Y Price Target: $11.67
• Price Target Upside: 9.17% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): 2.3
• Revenue Forecast (FY): $14.08B

• Rating: 60 Neutral
• Price Target: $12.00 ▲(12.25% Upside)

Viatris' overall stock score reflects a mix of positive technical momentum and strategic initiatives, offset by financial performance challenges and valuation concerns. The company's efforts to return capital to shareholders and advance its R&D pipeline are promising, but operational inefficiencies and negative earnings weigh on the score.

Positive Factors

R&D Advancements

Continued R&D advancements can lead to new product launches, enhancing Viatris' competitive edge and long-term revenue potential.

Capital Return to Shareholders

Strong capital return strategy reflects financial discipline and commitment to shareholder value, supporting investor confidence.

New Product Revenue Momentum

Growth in new product revenues indicates successful market penetration and potential for sustained revenue increases.

Negative Factors

Indore Facility Issues

Indore facility issues create operational uncertainties, potentially impacting revenue and operational efficiency.

Profitability Challenges

Negative profitability metrics indicate operational inefficiencies, which could hinder long-term financial health and growth.

Cash Flow Decline

Declining cash flow growth suggests potential liquidity issues, impacting the company's ability to invest in growth opportunities.

Viatris Business Overview & Revenue Model

Company Description

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

How the Company Makes Money

Viatris generates revenue primarily through the sale of prescription medicines, including generics, branded products, and biosimilars. Its revenue model is predominantly based on direct sales to healthcare providers, pharmacies, and hospitals, as well as partnerships with other pharmaceutical companies for co-marketing and distribution agreements. Key revenue streams include the sale of high-demand generic drugs, which are often less expensive alternatives to branded medications, and the ongoing development and commercialization of biosimilars that target biologic therapies. Additionally, Viatris benefits from strategic collaborations and partnerships that enhance its market reach and product offerings, contributing to its earnings and overall financial performance.

Viatris Financial Statement Overview

Summary

Viatris faces challenges with profitability and cash flow despite maintaining a stable leverage position. The company needs to address its operational inefficiencies and improve its profit margins to enhance financial health. While revenue shows some growth, the negative net income and declining cash flow growth are areas of concern that need strategic focus.

Income Statement

Viatris shows a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of 36.61%, which is decent but has declined from previous years. The net profit margin is negative at -24.57%, reflecting significant losses, and EBIT and EBITDA margins are also negative, indicating operational challenges. Revenue growth is slightly positive at 6.2% for the TTM, but historical data shows volatility with periods of decline.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.93 in the TTM, indicating a balanced leverage position. However, the return on equity is negative at -19.92%, suggesting inefficiencies in generating returns for shareholders. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets.

Cash Flow

Cash flow analysis shows a decline in free cash flow growth at -3.37% in the TTM, indicating potential liquidity issues. The operating cash flow to net income ratio is strong at 1.23, suggesting good cash generation relative to net income. The free cash flow to net income ratio is 0.83, which is reasonable but reflects the impact of negative net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.12B	14.74B	15.43B	16.26B	17.89B	11.95B
Gross Profit	5.09B	5.62B	6.44B	6.50B	5.58B	3.80B
EBITDA	-598.90M	2.82B	3.52B	6.43B	4.48B	1.99B
Net Income	-3.69B	-634.20M	54.70M	2.08B	-1.27B	-669.90M
Balance Sheet
Total Assets	37.92B	41.50B	47.69B	50.02B	54.84B	61.55B
Cash, Cash Equivalents and Short-Term Investments	1.11B	1.09B	1.18B	1.47B	935.00M	1.05B
Total Debt	14.72B	14.31B	18.37B	19.53B	23.36B	26.16B
Total Liabilities	22.70B	22.87B	27.22B	28.95B	34.35B	38.60B
Stockholders Equity	15.22B	18.64B	20.47B	21.07B	20.49B	22.95B
Cash Flow
Free Cash Flow	1.60B	1.98B	2.33B	2.51B	2.51B	550.60M
Operating Cash Flow	1.98B	2.30B	2.80B	3.00B	3.02B	1.23B
Investing Cash Flow	-385.20M	1.80B	-764.10M	1.47B	-117.80M	-301.10M
Financing Cash Flow	-2.48B	-4.33B	-2.30B	-3.88B	-3.01B	-605.70M

Viatris Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTRS, the sentiment is Positive. The current price of 10.69 is above the 20-day moving average (MA) of 10.47, above the 50-day MA of 10.14, and above the 200-day MA of 9.25, indicating a bullish trend. The MACD of 0.11 indicates Positive momentum. The RSI at 57.19 is Neutral, neither overbought nor oversold. The STOCH value of 60.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTRS.

Viatris Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RDY	73 Outperform	$11.75B	17.20	17.72%	0.65%	10.63%	6.35%
ANIP	64 Neutral	$1.91B	52.04	7.83%	―	48.87%	―
TEVA	63 Neutral	$30.07B	43.92	10.77%	―	-0.25%	―
AMRX	63 Neutral	$3.56B	788.19	―	―	9.50%	―
VTRS	60 Neutral	$12.31B	―	-21.09%	4.49%	-6.40%	-320.23%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	50 Neutral	$2.78B	―	-0.65%	8.69%	-2.55%	66.00%

Viatris Corporate Events

Viatris Inc. Reports Steady Q3 2025 Performance

Viatris Inc. is a global healthcare company that bridges the gap between generics and branded medicines, offering a wide range of pharmaceutical products worldwide. In its third-quarter 2025 earnings report, Viatris announced stable revenues and strategic advancements, including the acquisition of Aculys Pharma and progress in its late-stage pipeline. The company reported total revenues of $3.8 billion, consistent with the previous year, and highlighted a $920 million return of capital to shareholders. Despite a net loss driven by investment value reductions and increased tax expenses, Viatris continues to focus on strategic growth and operational efficiencies. Looking ahead, Viatris remains committed to its strategic priorities and anticipates sustainable growth through ongoing pipeline advancements and strategic reviews.

Viatris, Inc. Earnings Call: Mixed Sentiment and Strategic Focus

Viatris, Inc. recently held its earnings call, revealing a mixed sentiment with strong commercial performance and strategic R&D advancements, counterbalanced by challenges at the Indore facility and market declines. The company is actively working to address these issues while progressing in its strategic initiatives.

Viatris Reports Strong Q3 2025 Financial Results

On November 6, 2025, Viatris reported strong financial results for the third quarter of 2025, with total revenues aligning with expectations. The company made significant progress in its late-stage pipeline, including an NDA submission for a low-dose estrogen patch, and acquired Aculys Pharma, enhancing its market presence in Japan and the Asia-Pacific region. Viatris returned over $920 million to shareholders, raised its financial guidance for 2025, and is preparing for strategic actions to ensure sustainable growth beyond 2025.

The most recent analyst rating on (VTRS) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Viatris stock, see the VTRS Stock Forecast page.

Viatris Announces Approval of Amended Bylaws

On October 24, 2025, Viatris Inc. announced the approval of its Amended and Restated Bylaws, which became effective immediately. These changes include specifications for timely notice of proxy access nominations and procedures for shareholder nominations and proposals for the upcoming 2026 annual meeting. The company aims to enhance efficiency by holding the 2026 annual meeting on May 15, 2026, with specific guidelines for shareholder participation and nominations.

The most recent analyst rating on (VTRS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Viatris stock, see the VTRS Stock Forecast page.